Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARIXTRA vs Enoxaparin in Hip or Knee Replacement
NCT00328939Phase 3Completed
- Sponsor
- GSK
- Start
- May 2004
- Modality
- Allosteric Modulators
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial of fondaparinux in venous thromboembolism (VTE) (2 arms), sponsored by GSK. Primary endpoint: Occurrence of overall Deep Vein Thrombosis. Started May 2004; status: completed.
02
Drugs
fondaparinux
03
Conditions
venous thromboembolism (VTE)
Beyond the preview
Go deeper on NCT00328939.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00328939.